HIG has bought into UK generic and branded pharmaceutical supplier Aspire Pharma.
Aspire licenses and develops niche generic and specialty pharmaceutical products in underserved markets. It supplies 250 products across urology, ophthalmology, CNS and dermatology.
John Harper, managing director and head of the H.I.G. Europe Lower Middle Market LBO team in London, said, “We are delighted to be supporting Graham and his team to further build upon Aspire’s success. The company’s track record of identifying, developing and launching niche pharmaceutical products, coupled with HIG’s international presence and history of supporting organic and acquisitive growth in its portfolio companies, underpins an exciting next chapter for Aspire.”
HIG Capital raised €2bn for HIG Europe Middle Market LBO Fund earlier in the month. As the firm’s first mid-market European buyout fund, it targets businesses with valuations of up to €1bn, primarily in Western Europe.
The fund was already more than 25% committed across six investments at the time of closing.
HIG now manages more than $45bn across private equity, debt, infrastructure and real estate. The firm closed HIG Capital Partners VI on $1.3bn last year.
It also raised a $1.4bn credit fund in March to “capitalize on the compelling investment opportunities” available in the wake of Covid-19 volatility. The fund was already 25% committed at the time.
Copyright © 2021 AltAssets
